Abstract
The discovery that a subset of non-small cell lung cancers (NSCLC) were dependent upon reoccurring activating EGFR ( ErbB1 ) mutations (1-4), primarily deletions of exon 19 or an activating point mutation, L858R , ushered in the era of targeted therapies for lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
